Key result
Protein C mutation prevalence was notably high in patients with pulmonary emboli (42.8%) compared to those with deep vein thrombosis (8.33%) or cerebral vein thrombosis (16.1%).
Why the study?
What is the frequency of factor V, prothrombin, and protein C mutations in Turkish venous thrombosis patients compared to controls?
Case-Control (n=75)
What is the frequency of factor V, prothrombin, and protein C mutations in Turkish venous thrombosis patients compared to controls?
In Turkish patients with venous thrombosis, protein C deficiency appears to confer a greater risk of thrombosis, particularly pulmonary embolism, compared to factor V or prothrombin G20210A mutations.
Should not yet change thrombophilia testing; hypothesis-generating for site-specific protein C risk in Turkish venous thrombosis.
Several inherited polymorphisms are associated with risk of venous thrombosis, including mutation at codon 506 of the factor V gene, mutation at position 20210 of the prothrombin gene, and mutations in the protein C gene. In this study, genotyping for factor V, prothrombin, and protein C mutations was performed in 50 patients and 25 control subjects by polymerase chain reaction-based analysis. The prevalence of factor V and prothrombin mutations was not significantly different from that in the general population. Nine of the patients had heterozygous protein C mutation. There was a high prevalence of the mutated protein C allele in the pulmonary emboli group (42.8%). Protein C mutation incidence was higher in the pulmonary emboli group than in the deep vein thrombosis (8.33%) and cerebral vein thrombosis (16.1%) groups. These results indicate that patients with protein C deficiency have a greater risk of thrombosis than patients with factor V or prothrombin G20210A mutation.
No takes yet. Share an insight, caveat, or question.
Altınışık et al. (2007) conducted a case-control in Venous thrombosis (n=75). Genotyping for factor V, prothrombin, and protein C mutations vs. Control subjects was evaluated on Prevalence of factor V, prothrombin, and protein C mutations. Protein C mutation prevalence was notably high in patients with pulmonary emboli (42.8%) compared to those with deep vein thrombosis (8.33%) or cerebral vein thrombosis (16.1%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: